Interruption of the Enterohepatic Circulation of Digitoxin by Cholestyramine

II. EFFECT ON METABOLIC DISPOSITION OF TRITIUM-LABELED DIGITOXIN AND CARDIAC SYSTOLIC INTERVALS IN MAN

JAMES H. CALDWELL, CHARLES A. BUSH, and NORTON J. GREENBERGER

*From the Divisions of Gastroenterology and Cardiology, Department of
Medicine, The Ohio State University College of Medicine,
Columbus, Ohio 43210*

ABSTRACT Previous studies of digitalis glycoside metabolism and excretion have indicated that these compounds undergo a significant enterohepatic cycle in some species. It has been suggested that the existence of such a cycle in man contributes to the prolonged action of certain cardiac glycosides. Previous studies have demonstrated that cholestyramine binds digitoxin and digoxin in vitro and accelerates the metabolic disposition of digitoxin in rats and guinea pigs, presumably by interrupting the enterohepatic circulation.

In order to assess the role of the enterohepatic circulation in the metabolism of digitalis glycosides in humans, maintenance doses of cholestyramine were administered to 7 of 15 normal human subjects beginning 8 hr after digitalization with 1.2 mg of digitoxin-³H. All subjects had frequent measurements of serum radioactivity, left ventricular ejection time (LVET), and electromechanical systole (QS₂), the latter recorded as the interval from onset of Q wave to first major component of second heart sound. Measurement of the LVET and QS₂ intervals affords a sensitive index of the cardiac response to digitalis. In addition, chloroform extraction of serum was performed to separate unchanged digitoxin and active metabolites from cardioinactive metabolites of digitoxin. Cholestyramine treatment resulted in reduction in half-life to total serum radioactivity from 11.5 to 6.6 days, and in chloroform-extractable radioactivity from 6.0 to 4.5 days, as compared to controls. In addition, cholestyramine treatment was accompanied by more rapid return to base line values of digitoxin-induced changes in the LVET and QS₂ intervals. A sig-

nificant positive correlation was found between QS₂ values and chloroform-extractable radioactivity, the latter reflecting unchanged digitoxin-³H ($r=0.64$; $P<0.01$).

The results indicate that administration of cholestyramine to digitalized human subjects accelerates the metabolic disposition of digitoxin and abbreviates the physiologic response to the glycoside. This effect is presumably mediated by interruption of the enterohepatic circulation of digitoxin by cholestyramine.

INTRODUCTION

Recent studies from this laboratory (1) have demonstrated that cholestyramine, an anion exchange resin, binds substantial amounts of the cardiac glycosides digitoxin and digoxin in vitro. Further, in rats and guinea pigs, it was shown that pretreatment with cholestyramine provides appreciable protection against lethal doses of digitoxin (1). This effect, accompanied by accelerated fecal excretion and reduced levels of digitoxin in some tissues, is apparently mediated by interruption of the enterohepatic circulation of digitoxin. Although the original concept of the enterohepatic cycle of cardiac glycosides was proposed by Okita, Talso, Curry, Smith, and Geiling on the basis of early studies on the metabolism of these drugs in humans (2), the relevance of this enterohepatic circulation to clinical pharmacology has not been fully appreciated (3). This report describes studies carried out to evaluate the effects of pharmacologic interruption of the enterohepatic circulation of digitoxin in man by cholestyramine. The data obtained indicate that cholestyramine treatment causes a significant shortening of the metabolic half-life of circulating digitoxin-³H and enhanced dissipation of its cardiac effects as determined by serial changes in cardiac systolic intervals.

This work was presented in part at the 62nd Annual Meeting of The American Society for Clinical Investigation, May 1970, Atlantic City, N. J.

Received for publication 16 September 1970 and in revised form 12 August 1971.

METHODS

Materials. Tritium-labeled digitoxin¹ (SA 1.0 mCi/0.133 mg) was checked for purity by thin-layer chromatography and found to be >98% pure. Commercial digitoxin was obtained as Purodigin² in ampules containing 0.2 mg/ml in 40% alcohol. Cholestyramine was kindly supplied as a gift.³

Measurement of radioactivity. Blood was obtained from subjects by venipuncture and serum separated by centrifugation. Duplicate 0.5 ml portions of serum were added to 15.0 ml of Bray's solution (120 g naphthalene, 8 g PPO (2,5-diphenyloxazole), 400 mg POPOP (1,4-bis[2-(5-phenyloxazolyl)]-benzene), 200 ml absolute methanol, 40 ml ethylene glycol brought to a final volume of 2000 ml with *p*-dioxane) in polyethylene counting vials. Samples were counted in a Packard Tri-Carb scintillation spectrometer model 3375⁴ equipped with automatic external standardization. Counting efficiency was 20%. Enough counts were taken on each sample to assure a counting error of less than 3%.

Chloroform extraction of serum samples was carried out by a modification of the method of Katzung and Meyers (4). This method separates unchanged digitoxin-³H and its chloroform-soluble metabolites from the water-soluble metabolites. The major chloroform-soluble metabolite of digitoxin is digoxin (3, 5). The intermediary metabolites of digitoxin and digoxin have poorly established biologic activity and cannot usually be detected in vivo (6), as they are rapidly converted to water-soluble compounds with little or no biologic activity (6, 7). Chloroform extraction thus separates the labeled glycosides of the serum into a chloroform-soluble fraction containing primarily digitoxin and digoxin, and a water-soluble fraction containing degradation products of these substances. Duplicate 0.5 ml portions of serum were extracted with 1.5 ml chloroform, the aqueous phase removed by pipette and extracted twice more with 1.0 ml chloroform, and the chloroform phases pooled and rinsed into polyethylene counting vials with additional chloroform. The chloroform phase was allowed to evaporate in a hood at room temperature and 15.0 ml Bray's solution added to the radioactive residue and shaken. In preliminary experiments, 93-99% of digitoxin-³H added to control serum was recovered by this procedure.

Regression analysis of data on total and chloroform-extractable serum radioactivity was done by transformation of variables and linear regression using a modification of a Wang program (Wang Laboratories,⁵ CAL 360-STAT 6) and a Hewlett-Packard 9100 A calculator.⁶

Measurement of systolic intervals. Duration of the phases of electrical and mechanical systole was determined by the method of Weissler, Snyder, Schoenfeld, and Cohen (8). All subjects rested for at least 30 min in a quiet room and abstained from food, tobacco, or caffeine for 4 hr before each systolic interval determination. Simultaneous recordings of the electrocardiogram, phonocardiogram, and carotid arterial pulse were made on a multichannel recorder at a paper speed of 100 mm/sec with 20 msec time lines. The phonocardiogram was recorded from a Peiker microphone placed in a constant position on the chest for each

recording, at a point where clear inscription of both heart sounds could be detected. The carotid pulse tracing employed a funnel-shaped pickup connected to an air-filled Statham P23D6 transducer,⁷ placed over the point of maximal pulsation of the carotid artery.

The phases of systole determined from these measurements included (a) the QS₂ interval,⁸ which is defined as the interval from the onset of the Q wave to the first major component of the second heart sound and (b) the left ventricular ejection time (LVET), which is the interval from the upstroke to the incisura of the carotid arterial pulse tracing. Both intervals were corrected for heart rate (HR) using the regression equations derived from data previously obtained for normal male subjects (9):

$$\begin{aligned}QS_2 &= -2.1 \text{ HR} + 546, \\LVET &= -1.7 \text{ HR} + 413.\end{aligned}$$

The corrected LVET is known as the ejection time index (ETI). Deviations from the normal in QS₂ and LVET intervals were calculated as the difference between the observed interval and that predicted from the normal regression equation (ΔQS_2 , $\Delta LVET$). Corrections for diurnal variation in intervals recorded at 8 hr after ingestion of digitoxin was made by subtracting the mean 8 hr reduction in intervals measured in normal subjects from the observed 8 hr measurement (9). Statistical analyses were performed by use of the Student *t* test (10).

Experimental design. 15 healthy male medical students and physicians ranging in age from 21 to 35 served as volunteer subjects. All subjects were found to be normal on physical examination and had normal electrocardiograms. Subjects were divided at random into control and cholestyramine treatment groups before participation. On the morning of the first study day, the fasting subjects rested in a quiet room and had replicate base line measurements of systolic intervals performed. The subjects then ingested 1.2 mg of digitoxin-³H (100 μ Ci) in 40% ethyl alcohol. Serial blood samples were taken at 30, 60, and 90 min, 2, 4, 6, and 8 hr after ingestion of digitoxin-³H and at 24 hr intervals for 1 wk thereafter. Systolic intervals were recorded 4 and 8 hr after ingestion and at 24 hr intervals thereafter for 1 wk. In addition, the cholestyramine-treated subjects took 4 g cholestyramine 8, 12, and 16 hr after the dose of digitoxin-³H and four times daily thereafter for 5 days. Two control subjects noted nausea for a few minutes within 1 hr after ingestion of digitoxin-³H. Three cholestyramine-treated subjects noted slight constipation and one experienced nausea following the medication for the first 2 days. No subject considered the symptoms severe enough to warrant discontinuation of the study. No arrhythmias were recorded in either group during the study.

RESULTS

Effect of cholestyramine on blood levels of digitoxin-³H. Serum levels of total radioactivity after ingestion of 1.2 mg of digitoxin-³H in control and cholestyramine-treated subjects are shown in Fig. 1. It is apparent that maximal levels of radioactivity were

¹ New England Nuclear Corp., Boston, Mass.

² Wyeth Laboratories, Philadelphia, Pa.

³ Mead Johnson & Co., Evansville, Ind.

⁴ Packard Instrument Co., Inc., Downers Grove, Ill.

⁵ Wang Laboratories, Tewksbury, Mass.

⁶ Hewlett-Packard Co., Palo Alto, Calif.

⁷ Statham Instruments, Inc., Los Angeles, Calif.

⁸ Abbreviations used in this paper: ETI, ejection time index; HR, heart rate; LVET, left ventricular ejection time; QS₂ interval, interval from onset of Q wave to first major component of second heart sound.

FIGURE 1 Effect of cholestyramine treatment on total serum radioactivity after ingestion of 1.2 mg (100 μ Ci) of digitoxin- 3 H. The subjects received 16 g of cholestyramine daily for 7 days commencing 8 hr after ingestion of digitoxin. The values shown represent the mean $\pm$ 1 SD.

reached within 60–90 min after ingestion and that blood levels of digitoxin- 3 H were essentially similar through the first 8 hr, at which time the treatment group began taking cholestyramine. Thereafter the serum radioactiv-

ity fell more rapidly in the cholestyramine-treated subjects, and was significantly lower at 48 hr and at each time interval thereafter until the end of the study. It is important to note that serum radioactivity 8 hr after ingestion of digitoxin- 3 H averaged 5006 dpm/ml in control subjects and 5078 dpm/ml in subjects taking choles-

FIGURE 2 Effect of cholestyramine on the half-life ($t_{1/2}$) of total serum radioactivity after ingestion of 1.2 mg (100 μ Ci) of digitoxin- 3 H. The values shown are derived from the data in Table I.

FIGURE 3 Effect of cholestyramine on the half-life ($t_{1/2}$) of serum chloroform-extractable radioactivity after ingestion of 1.2 mg (100 μ Ci) of digitoxin- 3 H. The values shown are derived from the data in Table II.

TABLE I
Total Serum Radioactivity after Oral Administration of Digiloxin-³H*

Group	Hr after ingestion of digitoxin- ³ H	Serum radioactivity							t _{1/2}
		8	24	48	72	96	120	168	
		dpm/ml							days
1. Control Subjects									
1		4794	3978	3900	3420	3668	3540	2590	9.5
2		5384	4806	4672	—	4111	3972	3370	10.8
3		4318	3918	4072	3378	4348	3650	3002	16.4
4		5446	5320	5507	5006	4424	4393	3495	10.3
5		5135	4162	4203	3802	3725	2953	2886	8.4
6		5270	4880	4716	4654	3996	3920	3650	12.4
7		5910	4796	4746	4790	4038	3874	3942	12.2
8		3790	4330	3918	3816	3920	3372	2756	12.5
Mean		5006	4524	4467	4124	4029	3709	3211	11.5 ± 2.3§
2. Cholestyramine Subjects									
1		4539	4476	4520	3790	3386	3257	2801	8.7
2		4132	3464	3262	2650	2480	2038	1650	5.2
3		5714	4768	3562	3066	2388	2190	1814	4.0
4		4664	4572	4364	3892	3946	3258	2882	9.5
5		5452	5454	3734	3632	3436	2690	2216	5.1
6		6272	6549	5388	5316	4841	3605	3268	6.5
7		4772	3920	3362	3356	2993	2833	2194	6.9
Mean		5078	4743	4027	3672	3353	2839	2404	6.6 ± 1.9§

* Subjects received 1.2 mg of digitoxin-³H (100 μ Ci) in 40% ethyl alcohol. For further experimental details see text.

† t_{1/2} was calculated by regression analysis done by transformation of variables and linear regression using a modification of a Wang Program (Wang Laboratories, CAL 360-STAT 6).

§ Mean $\pm$ 1 SD.

tyramine. Since the specific activity of the ingested glycoside was 1.2 mg/100 μ Ci or 12 ng/2260 dpm, it was calculated that mean peripheral blood digitoxin-³H levels were 26.5 and 26.8 ng/ml in the two groups respectively, well within the range of values reported by others (11, 12) after a comparable dose of digitoxin.

Regression analysis of all the individual data points from which the mean values in Fig. 1 were derived was carried out for each individual subject using the formula $y = ae^{-bx}$ (Table I). The mean t_{1/2} for the slow linear process of decline of serum radioactivity was calculated to be 11.5 $\pm$ 2.3 ($\pm$ 1 SD) days in the control subjects and 6.6 $\pm$ 1.9 days in the cholestyramine-treated subjects ($t = 4.2$; $P < 0.01$). This reflects a substantial difference in the rate of metabolic clearance and excretion of digitoxin and metabolites from the blood in these two groups. Fig. 2 shows a semilogarithmic plot of the data in Table I and Fig. 1. Extrapolation of these two curves to zero time, and subtracting from the raw curve, permits one to draw a line representing the early phase of tissue distribution of the glycoside. This plot was virtually identical in both groups, the t_{1/2} being 2–3 hr. These observations indicate that cholestyramine, given in the usual maintenance doses, caused a significant reduction

in the half-life of total radioactivity-³H in acutely digitalized human subjects. As indicated above, total radioactivity-³H includes unchanged digitoxin, as well as cardioactive and inactive metabolites.

It will be recalled that chloroform extraction separates the labeled glycosides into a chloroform phase representing predominantly cardioactive compounds, including all of the unchanged digitoxin, and an aqueous phase containing essentially cardioinactive but radiolabeled metabolites. To determine whether cholestyramine caused a shortening of the half-life of cardioactive radioactivity, chloroform-extractable radioactivity in the serum was measured (Table II). The mean t_{1/2} of chloroform-soluble radioactivity in the control group was calculated to be 6.0 $\pm$ 0.9 days, approximating the physiological half-life reported by other investigators (7, 8). By contrast, the half-life of digitoxin-³H in the cholestyramine-treated group was significantly reduced to 4.5 $\pm$ 0.9 days ($t = 3.1$; $P < 0.01$). Fig. 3 shows a semilogarithmic plot of the data in Table II. The data clearly indicate that the reduction in total radioactivity seen in the cholestyramine-treated subjects was paralleled by a similar decrease in the level of cardioactive glycoside radioactivity, predominantly unchanged digitoxin.

TABLE II
Chloroform-Extractable Serum Radioactivity after Oral Administration* of Digiloxin-³H

Group	Hr after ingestion of digitoxin- ³ H	Chloroform extractable serum radioactivity							t‡‡
		8	24	48	72	96	120	168	
		dpm/ml							days
1. Control Subjects									
1		1396	2040	1143	973	1182	1055	637	5.4
2		2354	2200	2066	1800	1600	1260	1050	5.4
3		2129	1614	1535	1458	1437	1060	876	5.9
4		2500	2630	2300	2200	2056	1584	1500	7.8
6		2330	2544	1678	1780	1700	1818	762	4.9
7		1638	1600	1516	1592	1234	1000	780	6.1
8		2302	2270	2256	1698	2020	1342	1182	6.4
Mean		2092	2128	1785	1616	1604	1303	913	6.0 ±0.9§
2. Cholestyramine Subjects									
1		1574	1906	1176	1008	1044	962	796	6.0
2		2247	2689	2000	1569	1462	1408	1073	5.4
3		2324	1722	1430	1266	958	422	718	3.5
4		1446	1154	764	632	652	728	592	4.7
5		2818	2395	1805	1745	1284	1198	743	3.8
6		2254	1902	1540	1287	1055	1092	780	4.5
7		2071	1893	1539	1218	1053	933	618	3.8
Mean		2105	1952	1465	1246	1044	963	760	4.5 ±0.9§

* For further details see text and Table I.

† Calculated by regression analysis. For further details see text and Table I.

§ Mean ± 1 SD.

Effect of cholestyramine on systolic intervals. Data on the ejection time index from 8 hr to 5 days after ingestion of 1.2 mg digitoxin by control and cholestyramine-treated subjects is summarized in Table III. It can be seen that at 24 hr both groups of subjects had virtually identical reduction in LVET from control levels (14.5 ± 1.7 vs. 14.5 ± 2.3 msec). These values at 24 hr are very similar to that previously reported following oral ingestion of 1.6 mg digitoxin (15 ± 2.1 msec) (8). Thereafter, the values in the cholestyramine-treated subjects return toward normal much more rapidly than those in the control subjects.

Weissler and Schoenfeld have recently presented evidence that the QS_2 interval is a more constant and specific index of cardiac digitalis effect (9). The effect of cholestyramine on the digitoxin-induced changes in the QS_2 interval in the same groups of subjects is seen in Table III and Fig. 4. It can be seen that while values for ΔQS_2 are similar at 8 hr (19.6 ± 3.0 vs. 20.3 ± 2.7 msec), the further decrease in ΔQS_2 values is accelerated in the subjects taking cholestyramine. The values in the cholestyramine-treated subjects are significantly different from those in the control subjects 4 and 5 days after digitalization. These data indicate

FIGURE 4 Effect of cholestyramine treatment on the QS_2 systolic interval following ingestion of 1.2 mg digitoxin. The subjects received cholestyramine as described in the text and Fig. 1.

that cholestyramine accelerates the dissipation of contractile responses to digitoxin in a manner similar to the reduction in peripheral blood levels of digitoxin-³H.

To further corroborate the relationship between blood levels of digitoxin-³H and physiologic response, individual values for simultaneously determined QS₂ and chloroform extractable radioactivity were compared by regression analysis (Fig. 5). It can be seen that there is a significant correlation between the serum radioactivity and the abbreviation of electromechanical systole due to digitoxin ($r = 0.654$, $P < 0.01$). The apparent wider dispersion of points at Δ QS₂ values less than 10 msec probably reflects the relatively greater difficulty in accurately measuring the small changes in QS₂ found in the cholestyramine-treated subjects in the latter part of the study. The data indicate that there is a positive correlation between myocardial electromechanical response and peripheral blood cardiac glycoside levels, the latter presumably reflecting myocardial digitoxin levels.

DISCUSSION

Recent studies concerned with the metabolism and clinical pharmacology of the cardiac glycosides have suggested that enterohepatic circulation of these drugs may influence the duration of action of a given compound (13). The studies reported herein were performed in order to determine whether pharmacologic interruption of this enterohepatic cycle was feasible in the acutely digitalized human subject. Determinations of total radioactivity and chloroform-soluble radioactivity in peripheral blood following the ingestion of digitoxin-³H were carried out in control and cholestyramine-treated subjects. These data provide a means for determining whether oral administration of a binding agent such as cholestyramine would influence peripheral blood levels of cardioactive labeled glycoside in the digitalized human. In addition, measurement of systolic intervals in these subjects afforded a means of assessing the physiologic effects of digitoxin on the heart and permitted comparison between simultaneous blood level of digitoxin and cardiac responses. The systolic interval determinations have been shown to be a predictable and dose-dependent measurement of physiologic response of the heart to cardiac glycosides (8), and thus provide an additional parameter by which the effects of cholestyramine can be assessed.

The parallel reduction in digitoxin blood levels (Figs. 1-3) and contractile response to digitoxin (Fig. 4) in the cholestyramine-treated subjects clearly indicate that such treatment shortens the metabolic half-life and enhances the physiologic dissipation of the cardiac effects of digitoxin. There are several lines of evidence indicating that these effects are the result of interrup-

FIGURE 5 Correlation between the QS₂ systolic interval and serum chloroform extractable radioactivity following ingestion of 1.2 mg (100 μ Ci) of digitoxin-³H. Cholestyramine treatment was as described in the text and Fig. 1.

tion of the enterohepatic circulation of digitoxin. First, it has been established that cholestyramine binds appreciable amounts of cardiac glycosides in vitro (1). Second, protective effects have been demonstrated in experimental animals pretreated with cholestyramine and then given lethal doses of digitoxin by subcutaneous injection (1). Third, orally administered cholestyramine has been shown to accelerate the fecal excretion of parenterally administered digitoxin-³H (1).

TABLE III
Effect of Cholestyramine on Digitoxin-Induced Changes in Electromechanical Systole (QS₂) and Ejection Time Index (ETI)*

Time	Changes in electromechanical systole (Δ QS ₂)		Changes in ejection time index (Δ ETI)	
	Control (8)	Cholestyramine (7)	Control (8)	Cholestyramine (7)
	msec		msec	
8 hr	19.6 $\pm$ 3.0†	20.3 $\pm$ 2.7	18.2 $\pm$ 2.5	14.4 $\pm$ 3.9
1 day	26.0 $\pm$ 2.1	18.9 $\pm$ 2.9	14.5 $\pm$ 1.7	14.5 $\pm$ 2.3
2 days	19.3 $\pm$ 1.3	17.7 $\pm$ 3.6	15.1 $\pm$ 1.7	11.7 $\pm$ 3.2
3 days	17.8 $\pm$ 1.7	15.3 $\pm$ 2.4	12.5 $\pm$ 0.8	12.2 $\pm$ 1.9
4 days	17.3 $\pm$ 1.1	10.9 $\pm$ 1.8§	13.4 $\pm$ 0.8	5.6 $\pm$ 2.4
5 days	15.3 $\pm$ 0.6	7.1 $\pm$ 2.5¶	14.1 $\pm$ 1.4	3.0 $\pm$ 2.3

* The QS₂ and ETI data are expressed as milliseconds' difference from average of triplicate base line determinations. Numbers in parentheses refer to numbers of subjects.

† Mean $\pm$ 1 SE.

§ $P < 0.05$.

|| $P < 0.01$.

¶ $P < 0.02$.

Fourth, in the human studies described on this report, the 8 hr interval between administration of digitoxin and initiation of cholestyramine treatment allows for complete absorption, distribution, and tissue uptake of the glycoside to occur before the first dose of the resin. This would seem to exclude the possibility that the cholestyramine effects were due to interference with the initial absorption of the glycoside. Fifth, no changes in serum electrolytes that might alter cardiac responsiveness to digitoxin are known to occur following cholestyramine (1). Finally, there is no evidence that cholestyramine affects the hepatic metabolism of cardiac glycosides.

Goldfinger, Heizer, and Smith (14) have recently presented evidence that cholestyramine administered concurrently with oral maintenance doses of digitoxin or digoxin results in lowered serum levels of the glycoside, presumably as a result of *direct* interference with absorption of the drug. Although the method used by these investigators does not allow estimation of the role of the enterohepatic circulation in human cardiac glycoside metabolism, some of their results are pertinent in regard to the present study. For example, they have performed in vitro binding studies that corroborate the results reported from this laboratory (1). They have also demonstrated that cholestyramine binds considerable amounts of digitoxin and digoxin in the intestinal lumen of man, resulting in reduced serum levels of these glycosides. In addition, they have demonstrated normal absorption of digoxin in one patient with complete biliary occlusion. This preliminary evidence that bile is not required for the normal intestinal absorption of digitalis confirms earlier animal studies from this laboratory (15). Furthermore, such data suggest that the direct binding of cardiac glycosides by cholestyramine is sufficient to account for the interference with glycoside absorption observed in this and other studies (1). It does not seem necessary to postulate that the cholestyramine-induced inhibition of glycoside absorption is mediated by the binding of bile salts.

The data obtained in this study provide indirect evidence for the existence of a significant enterohepatic cycle for digitoxin in humans. Furthermore, our observations suggest that the enterohepatic circulation of digitoxin contributes to the prolonged action characteristic of this glycoside. Finally, it was demonstrated that cholestyramine treatment caused a significant shortening of the metabolic half-life and enhanced physiologic dissipation of the cardiac effects of digitoxin, the latter measured by serial changes in systolic intervals. It is suggested that these effects were caused by intraluminal binding of digitoxin by cholestyramine with resultant interruption of the enterohepatic cycle of this

glycoside. However, it remains to be established whether such pharmacologic interruption of the enterohepatic circulation of digitoxin will prove to be of value in the treatment of patients with digitalis intoxication.

ACKNOWLEDGMENTS

We gratefully acknowledge the expert technical assistance of Mrs. Barbara VanAntwerp. We are indebted to Dr. Bernard Marks and Dr. George Okita for critical review of the manuscript and to Dr. Arnold Weissler for his encouragement and advice.

This work was supported by grants from the Central Ohio Heart Association and Warren-Teed Products Co., Columbus, Ohio.

REFERENCES

1. Caldwell, J. H., and N. J. Greenberger. 1970. Cholestyramine enhances digitalis excretion and protects against lethal intoxication. *J. Clin. Invest.* **49**: 16 a. (Abstr.)
2. Okita, G. T., P. J. Talso, J. H. Curry, F. D. Smith, Jr., and E. M. K. Geiling. 1955. Metabolic fate of radioactive digitoxin in human subjects. *J. Pharmacol. Exp. Ther.* **115**: 371.
3. Doherty, J. E. 1968. The clinical pharmacology of digitalis glycosides: a review. *Amer. J. Med. Sci.* **255**: 382.
4. Katzung, B. G., and F. H. Meyers. 1965. Excretion of radioactive digitoxin by the dog. *J. Pharmacol. Exp. Ther.* **149**: 257.
5. Katzung, B. G., and F. H. Meyers. 1966. Biotransformation of digitoxin in the dog. *J. Pharmacol. Exp. Ther.* **154**: 575.
6. Repke, K. 1963. Metabolism of cardiac glycosides. In *New Aspects of Cardiac Glycosides*. W. Wilbrandt, editor. The Macmillan Company, New York. 55.
7. Jelliffe, R. W., J. Buell, R. Kalaba, R. Sridhar, R. Rockwell, and J. G. Wagner. 1970. An improved method of digitoxin therapy. *Ann. Intern. Med.* **72**: 453.
8. Weissler, A. M., J. R. Snyder, C. D. Schoenfeld, and A. Cohen. 1966. Assay of digitalis glycosides in man. *Amer. J. Cardiol.* **17**: 768.
9. Weissler, A. M., and C. D. Schoenfeld. 1970. Effect of digitalis on systolic time intervals in heart failure. *Amer. J. Med. Sci.* **259**: 4.
10. Snedecor, G. W., and W. G. Cochran. 1956. *Statistical Methods Applied to Experiments in Agriculture and Biology*. The Iowa State University Press, Ames. 5th edition.
11. Lukas, D. S., and R. E. Peterson. 1966. Double isotope dilution derivative assay of digitoxin in plasma, urine, and stool of patients maintained on the drug. *J. Clin. Invest.* **45**: 782.
12. Smith, T. W., and E. Haber. 1970. Current techniques for serum or plasma digitalis assay and their potential clinical application. *Amer. J. Med. Sci.* **259**: 301.
13. Okita, G. T. 1967. Species differences in duration of action of cardiac glycosides. *Fed. Proc.* **26**: 1125.
14. Goldfinger, S. E., W. D. Heizer, and T. W. Smith. 1970. Malabsorption of digoxin in malabsorption syndromes. *Gastroenterology*. **58**: 952.
15. Greenberger, N. J., R. P. MacDermott, J. F. Martin, and S. Dutta. 1969. Intestinal absorption of six tritium-labeled digitalis glycosides in rats and guinea pigs. *J. Pharmacol. Exp. Ther.* **167**: 265.